EFFICACY AND TOLERABILITY OF TRANSVENOUS LOW-ENERGY CARDIOVERSION OF PAROXYSMAL ATRIAL-FIBRILLATION IN HUMANS

被引:209
|
作者
MURGATROYD, FD
SLADE, AKB
SOPHER, SM
ROWLAND, E
WARD, DE
CAMM, AJ
机构
[1] St. George's Hospital Medical School, London, England
关键词
D O I
10.1016/0735-1097(94)00555-5
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives. This study investigated the efficacy and tolerability of low energy shocks for termination of atrial fibrillation in patients, using an endocardial electrode configuration that embraced both atria. Background. In animals, low energy biphasic shocks delivered between electrodes in the coronary sinus and right atrium have effectively terminated atrial fibrillation. If human defibrillation thresholds are sufficiently low, atrial defibrillation could be achieved in conscious patients using an implanted device. Methods. Twenty-two consecutive patients with stable atrial fibrillation were studied during electrophysiologic testing. Biphasic R wave synchronous shocks were delivered between large surface area electrodes in the coronary sinus and high right atrium, using a step-up voltage protocol starting at 10 or 20 V and increasing to a maximum of 400 V. Patients were conscious at the start of the study and were asked to report on symptoms but were sedated later if shocks were not tolerated. Results. Cardioversion was achieved in all 19 patients who completed the study, with a mean (+/-SD) leading-edge voltage of 237 +/- 55 V (range 140 to 340) and mean energy of 2.16 +/- 1.02 J (range 0.7 to 4.4). The mean maximal shock delivered without sedation was 116 +/- 51 V (range 60 to 180). No proarrhythmia or mechanical complications occurred. Conclusions. The delivery of biphasic R wave synchronous shocks between the high right atrium and coronary sinus can terminate atrial fibrillation with very low energies, General anaesthesia is not required, and a minority of fully conscious patients are able to tolerate this method of cardioversion.
引用
收藏
页码:1347 / 1353
页数:7
相关论文
共 50 条
  • [21] PAROXYSMAL ATRIAL-FIBRILLATION
    CARLETON, RA
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1980, 244 (08): : 835 - 835
  • [22] ANTICOAGULATION FOR CARDIOVERSION OF ATRIAL-FIBRILLATION
    WEINBERG, DM
    MANCINI, GBJ
    AMERICAN JOURNAL OF CARDIOLOGY, 1989, 63 (11): : 745 - 746
  • [23] CARDIOVERSION OF ATRIAL-FIBRILLATION BY DISOPYRAMIDE
    RULLIERE, R
    DELEPIERRE, F
    COEUR ET MEDECINE INTERNE, 1972, 11 (03): : 581 - +
  • [24] A comparison of treatment of atrial fibrillation with low-energy intracardiac cardioversion and conventional external cardioversion
    Alt, E
    Ammer, R
    Schmitt, C
    Evans, F
    Lehmann, G
    Pasquantonio, J
    Schomig, A
    EUROPEAN HEART JOURNAL, 1997, 18 (11) : 1796 - 1804
  • [25] CARDIOVERSION IN PATIENTS WITH ATRIAL-FIBRILLATION
    KUCK, KH
    ZEITSCHRIFT FUR KARDIOLOGIE, 1994, 83 : 59 - 62
  • [26] CARDIOVERSION IN CHRONIC ATRIAL-FIBRILLATION
    不详
    LANCET, 1972, 1 (7758): : 1002 - +
  • [27] INDICATIONS FOR CARDIOVERSION OF ATRIAL-FIBRILLATION
    DUNN, M
    JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1972, 219 (09): : 1223 - &
  • [28] EVALUATION OF DRUG EFFICACY FOR PREVENTING PAROXYSMAL ATRIAL-FIBRILLATION
    FUJIKI, A
    YOSHIDA, S
    TANI, M
    SASAYAMA, S
    JAPANESE CIRCULATION JOURNAL-ENGLISH EDITION, 1992, 56 : 1454 - 1457
  • [29] EFFICACY AND SAFETY OF PROPAFENONE IN PATIENTS WITH PAROXYSMAL ATRIAL-FIBRILLATION
    KUO, K
    CHENARIDES, J
    CHIRAS, L
    HUANG, SK
    CLINICAL RESEARCH, 1990, 38 (03): : A781 - A781
  • [30] TRANSVENOUS LOW-ENERGY CARDIOVERSION FOR THE TREATMENT OF VENTRICULAR TACHYCARDIAS
    FROHNER, K
    KALTENBRUNNER, W
    PODCZECK, A
    STEINBACH, K
    PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY, 1985, 8 (03): : A39 - A39